Nephrology

November 23, 2022

Using data from a trio of trials, investigators provide insight into the potential benefits of combination therapy with SGLT2 inhibitors and RAAS inhibition on event-free survival among patients with chronic kidney disease without diabetes.

October 15, 2022

Kim Zuber, PA-C, and Jane Davis, DNP, provide perspective on the new National Kidney Foundation and the American Society of Nephrology formula for calculating eGFR.

August 09, 2022

An analysis of patient data from the Chronic Renal Insufficiency Cohort Study suggests increased levels of serum aldosterone were associated with an increased risk of chronic kidney disease progression.

July 30, 2022

Our cardiology month in review spotlights the most popular content from the past month. The top content from July 2022 includes hormone therapy guidance from NAMS, a look at the potential for increased risk of kidney damage with a popular statin, and a recap of upcoming decisions and trials of interest in cardiometabolic from the second half of 2022.

July 23, 2022

In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.

July 20, 2022

A secondary analysis of the DECLARE-TIMI 58 trial details the cardiorenal protective benefits of dapagliflozin across subgroups of patients defined by use of background cardiovascular medication use.

July 14, 2022

A comparison of data from more than 340,000 Medicare beneficiaries with diabetes provides insight into the real-world differences in the management of these patients, including disparities in the prescription of GLP-1 RAs and SGLT2 inhibitors.

July 13, 2022

An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.

July 06, 2022

A recent analysis of the ISCHEMIA program suggests invasive management of chronic coronary disease appeared to provide a greater degree of benefit in those with less advanced stages of chronic kidney disease.

June 24, 2022

New research from Indiana University details the impact of an invasive management strategy compared to medical management among patients with NSTEMI and chronic kidney disease across the spectrum of CKD severity.